Global private equity and venture capital news and research

Posts Tagged ‘Forbion Capital Partners’

28 September 2015

Atlas Venture-led consortium helps fund latest Replimune cancer research

lab-217041_1280 Early-stage investment firm Atlas Venture has headed a group of investors to successfully close a $30m financing round for Oxford-based cancer therapeutics firm Replimune.

17 September 2015

Forbion agrees exit of cholesterol drug developer Dezima for up to $1.55bn

fried-eggs-456351_1280 Dutch healthcare investment firm Forbion Capital Partners has agreed to $1.55bn sale of biotech business Dezima Pharma to trade player Amgen Inc.

11 September 2015

Coller, Hamilton Lane, others back Forbion co-investment fund

money-515058_1280 Life sciences-focused venture capital firm Forbion Capital Partners has held a €75m final close for a new co-investment fund aimed at backing later-stage deals in the portfolio of its second flagship fund.

8 September 2015

Ysios Capital leads €36.6m Series C for drug developer Sanifit

pills-530372_1280 Spanish early-stage investment firm Ysios Capital has led a €36.6m Series C investment round for clinical-stage biopharma business Laboratoris Sanifit.

26 May 2015

Quebec development capital fund FTQ makes €10.5m Forbion III commitment

life science green Quebec-focused development capital fund Fonds de solidarité FTQ has committed €10.5m to Forbion Capital Partners' third fund in an attempt to attract life sciences investment to the province.

24 March 2015

New VCs help anti-cancer treatment pioneer Rigontec push Series A to €14.25m

Dutch early stage investor Forbion Capital Partners and Danish peer Sunstone Capital have brought biopharma business Rigontec's Series A round to €14.25m through a second close.

5 August 2014

Forbion exits 2006 investment in Santaris to Roche for up to €450m

santaris Dutch early stage investment firm Forbion Capital Partners has sold Danish biopharmaceutical company Santaris Pharma to Roche in a deal worth up to $450m.

7 February 2014

Gene therapy company uniQure raises over $80m via IPO

biotech_lrg Venture capital-backed gene therapy specialist uniQure has raised nearly $82m via an IPO on the Nasdaq exchange, which was priced above the indicative range.

3 January 2014

Gene therapy company uniQure plans $75m Nasdaq IPO

stocks2_lrg Venture capital-backed gene therapy specialist uniQure plans to raise $75m via an IPO on the Nasdaq exchange, according to a filing with US securities regulators.

15 October 2012

Biotech company Promedior seals $24.5m Series D

Clinical stage biotechnology company Promedior has completed a $24.5m Series D financing round, adding $3m from corporate venture capital firm Shire Strategic Investment Group.

Legals & Terms of UsePrivacy Policy

AltAssets is registered as a trademark of Investor Networks Limited (06695690).
Registered Office: Zetland House, 5-25 Scrutton St, London EC2A 4HJ
Content is © AltAssets 2000-2015